CN109071637B - 结合严重发热伴血小板减少综合征病毒的包膜糖蛋白的抗体及其用途 - Google Patents
结合严重发热伴血小板减少综合征病毒的包膜糖蛋白的抗体及其用途 Download PDFInfo
- Publication number
- CN109071637B CN109071637B CN201780020024.5A CN201780020024A CN109071637B CN 109071637 B CN109071637 B CN 109071637B CN 201780020024 A CN201780020024 A CN 201780020024A CN 109071637 B CN109071637 B CN 109071637B
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001535172 Severe fever with thrombocytopenia virus Species 0.000 title claims abstract description 102
- 101710121417 Envelope glycoprotein Proteins 0.000 title claims abstract description 64
- 102100021696 Syncytin-1 Human genes 0.000 title claims abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 12
- 238000003745 diagnosis Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 2
- 208000011361 Severe Fever with Thrombocytopenia Syndrome Diseases 0.000 abstract description 35
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 87
- 102100034349 Integrase Human genes 0.000 description 60
- 238000000034 method Methods 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 23
- 241000700605 Viruses Species 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 16
- 238000001514 detection method Methods 0.000 description 15
- 108090000288 Glycoproteins Proteins 0.000 description 14
- 102000003886 Glycoproteins Human genes 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 101100450694 Arabidopsis thaliana HFR1 gene Proteins 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 210000003501 vero cell Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000010185 immunofluorescence analysis Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 2
- 241001480796 Haemaphysalis Species 0.000 description 2
- 241000179420 Haemaphysalis longicornis Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- 241000713137 Phlebovirus Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 239000003070 absorption delaying agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPNZBYLXNYPRLR-UHFFFAOYSA-N 2-(4-carbamimidoylphenyl)-1h-indole-6-carboximidamide;hydron;dichloride Chemical compound Cl.Cl.C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FPNZBYLXNYPRLR-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100022187 Caenorhabditis elegans mab-10 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101800000342 Glycoprotein C Proteins 0.000 description 1
- 101800000343 Glycoprotein N Proteins 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 101000900206 Hantaan virus (strain 76-118) Envelopment polyprotein Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 102400001263 NT-proBNP Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- -1 argon ion Chemical class 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/175—Bunyaviridae, e.g. California encephalitis virus, Rift valley fever virus, Hantaan virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/00029—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor provided with flat sample substrates, e.g. slides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/0098—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
SEQ ID NO | 抗体和位点 | 序列 |
11 | Ab1的LFR1 | ELTLTQSPATLSLSPGETATLSC |
12 | Ab2的LFR1 | ELVVTQPPSVSGAPGQRVTISC |
13 | Ab3的LFR1 | ELELTQPPSVSGAPGQRVTISC |
14 | Ab4的LFR1 | ELVLTQPPSASGTPGQRVTISC |
15 | Ab5的LFR1 | ELVVTQEPSLTVPPGGTVTLTC |
16 | Ab1的HFR1 | QVQLVQSGPEVKKPGSSVKVSCKAS |
17 | Ab2的HFR1 | EVQLVESGGGLVKPGGSLRLSCAAS |
18 | Ab3的HFR1 | QVQLQESGPGLVKPSETLSLTCTVS |
19 | Ab4的HFR1 | EVQLVESGGGLVQPGGSLRLSCAAS |
20 | Ab5的HFR1 | QVQLVQSGGGLVQPGGSLRLSCSAS |
SEQ ID NO | 抗体和位点 | 序列 |
31 | Ab1的LFR2 | WYQQKPGLAPRLLIY |
32 | Ab2的LFR2 | WYQQLPGTAPKLLIY |
33 | Ab3的LFR2 | WYQQLPGTAPKLLrY |
34 | Ab4的LFR2 | WYQQLPGTAPKLLIY |
35 | Ab5的LFR2 | WFQQKPGQAPRTLIY |
36 | Ab1的HFR2 | WVRQAPGQGLEWMG |
37 | Ab2的HFR2 | WVRQAPGKGLEWVS |
38 | Ab3的HFR2 | WIRQPPGKGLEWIG |
39 | Ab4的HFR2 | WVRQAPGKGLEWVS |
40 | Ab5的HFR2 | WVRQAPGKGLEYVS |
SEQ ID NO | 抗体和位点 | 序列 |
51 | Ab1的LFR3 | GIPDRFSGSGSGTDFTLTISRLAPEDSAVYYC |
52 | Ab2的LFR3 | GVPDRFSGSKSGTSASLAITGLQADDEADYYC |
53 | Ab3的LFR3 | GVPDRFSGSKSDTSASLAISGLRSEDEADYYC |
54 | Ab4的LFR3 | GVPDRFSGSKSGTSASLAISGLQSEDEADYYC |
55 | Ab5的LFR3 | WTPARFSGSLLGGKAALTLSGAQPEDDA-YYC |
56 | Ab1的HFR3 | RVTITADESTSTAYMELSSLRSEDTAVYYCA |
57 | Ab2的HFR3 | RFTISRDNAKNSLYLQMNSLRAEDTAVYYCA |
58 | Ab3的HFR3 | RVTISVDTSKNQFSLKLSSVTAADTAVYYCA |
59 | Ab4的HFR3 | RFTISRDNAKNSLYLQMNSLRAEDTAVYY-- |
60 | Ab5的HFR3 | RFTISRDNSKNTLYLQMSSLRAEDTAVYYCV |
SEQ ID NO | 抗体和位点 | 序列 |
71 | Ab1的LFR4 | FGGGTKLEIK |
72 | Ab2的LFR4 | FGGGTKLTVL |
73 | Ab3的LFR4 | FGGGTKLTVL |
74 | Ab4的LFR4 | FGTGTKVTVL |
75 | Ab5的LFR4 | FGGGTKLTVL |
76 | Ab1的HFR4 | QGTLVTVSS |
77 | Ab2的HFR4 | QGTMVTVSS |
78 | Ab3的HFR4 | QGTLVTVSS |
79 | Ab4的HFR4 | QGTMVTVSS |
80 | Ab5的HFR4 | QGTLVTVSS |
SEQ ID NO | 抗体和位点 | 序列 |
91 | Ab6的LFR1 | ELALTQPPSVSVAPGKTAK1TC |
92 | Ab7的LFR1 | ELVLTQPPSVSAAPGQKVTISC |
93 | Ab8的LFR1 | ELALTQPPSVSVAPAMTAKITC |
94 | Ab9的LFR1 | ELELTQPPSVSGTPGKRVSMSC |
95 | Ab10的LFR1 | ELVMTQSPSSLSASVGDTVTITC |
96 | Ab6的HFR1 | QVQLVQSGAEVKKPGESLKISCKGS |
97 | Ab7的HFR1 | QVQLVQSGAEVKKPGESLKISCKGS |
98 | Ab8的HFR1 | QVQLVQSGAEVKKPGESLKISCKGS |
99 | Ab9的HFR1 | QVQLVQSGAEVKKPGESLKISCKGS |
100 | Ab10的HFRI | EVQLVESGGGVVQPGRSLRLSCAAS |
SEQ ID NO | 抗体和位点 | 序列 |
111 | Ab6的LFR2 | WYQQTSGQAPVLVVY |
112 | Ab7的LFR2 | WYQQLPGTAPKLLIY |
113 | Ab8的LFR2 | WYQQTSGQAPVLVVY |
114 | Ab9的LFR2 | WYQQLPGKAPKLFIY |
115 | Ab10的LFR2 | WYHQTPGKAPKLLIS |
116 | Ab6的HFR2 | WVRQMPGKGLEWM |
117 | Ab7的HFR2 | WVRQMPGKGLEWM |
118 | Ab8的HFR2 | WVRQMPGKGLEWM |
119 | Ab9的HFR2 | WVRQLPGKGLEWM |
120 | Ab10的HFR2 | WVRQAPGKGLEWV |
SEQ ID NO | 抗体和位点 | 序列 |
131 | Ab6的LFR3 | GIPERFSGANSGNTATLTISRVEAGDEADYYC |
132 | Ab7的LFR3 | GIPDRFSGSKSGTSATLDITGLQTGDEADYYC |
133 | Ab8的LFR3 | GIPERFSGANSGNTATLTISRVEAGDEADYYC |
134 | Ab9的LFR3 | GVPDRVSGSKSGTSVSVAISGLQPEDEADYYC |
135 | Ab10的LFR3 | GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC |
136 | Ab6的HFR3 | QVTISADRSISTAYLQWSSLKASDTAMYYCA |
137 | Ab7的HFR3 | QVTISADKSISTAYLQWSSLKASDTAMYYCA |
138 | Ab8的HFR3 | QVTISADRSISTANLQWSSLKASDTALYYCA |
139 | Ab9的HFR3 | QVTISADKSISTAYLQWSSLKASDTAMYYCA |
140 | Ab10的HFR3 | RFTISRDNSKNTLYLQMNSLRAEDTAVYYCA |
SEQ ID NO | 抗体和位点 | 序列 |
151 | Ab6的LFR4 | FGGGTKLTVL |
152 | Ab7的LFR4 | FGSGTKLTVL |
153 | Ab8的LFR4 | FGGGTKLTVL |
154 | Ab9的LFR4 | FGGGTQLTVL |
155 | Ab10的LFR4 | FGGGTKLEIK |
156 | Ab6的HFR4 | QGTLVTVSS |
157 | Ab7的HFR4 | QGTLVTVSS |
158 | Ab8的HFR4 | QGTLVTVSS |
159 | Ab9的HFR4 | QGTLVTVSS |
160 | Ab10的HFR4 | QGTLVTVSS |
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160034727 | 2016-03-23 | ||
KR10-2016-0034727 | 2016-03-23 | ||
PCT/KR2017/003156 WO2017164678A2 (ko) | 2016-03-23 | 2017-03-23 | 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109071637A CN109071637A (zh) | 2018-12-21 |
CN109071637B true CN109071637B (zh) | 2022-03-22 |
Family
ID=59900424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780020024.5A Active CN109071637B (zh) | 2016-03-23 | 2017-03-23 | 结合严重发热伴血小板减少综合征病毒的包膜糖蛋白的抗体及其用途 |
Country Status (8)
Country | Link |
---|---|
US (2) | US10947299B2 (zh) |
EP (1) | EP3434690A4 (zh) |
JP (2) | JP7328479B2 (zh) |
KR (3) | KR20210019491A (zh) |
CN (1) | CN109071637B (zh) |
AU (2) | AU2017237543B2 (zh) |
MY (1) | MY196095A (zh) |
WO (1) | WO2017164678A2 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210019491A (ko) * | 2016-03-23 | 2021-02-22 | 서울대학교산학협력단 | 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도 |
KR102097994B1 (ko) * | 2018-04-25 | 2020-04-07 | 아이디바이오 주식회사 | 신규한 중증열성혈소판감소증후군 바이러스 |
CN112105637B (zh) * | 2019-07-23 | 2022-12-06 | 源道隆(苏州)医学科技有限公司 | 可结合sftsv的纳米抗体及其应用 |
CN110437332B (zh) * | 2019-08-20 | 2020-03-06 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种抗病毒感染的sftsv蛋白结合分子 |
CN110437333B (zh) * | 2019-08-20 | 2020-04-28 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | Sftsv抑制剂及其应用 |
KR102545412B1 (ko) * | 2019-09-24 | 2023-06-21 | 서울대학교산학협력단 | 중증열성혈소판감소증후증 바이러스에 대한 백신 조성물 |
AU2021205249A1 (en) * | 2020-01-08 | 2022-07-21 | Board Of Regents, The University Of Texas System | A method of engineering natural killer cells to target CD70-positive tumors |
CN113249334B (zh) * | 2021-03-16 | 2023-12-08 | 贵州省人民医院 | 一种分泌抗发热伴血小板减少综合征病毒单克隆抗体的杂交瘤细胞株sftsn5g12 |
US20240182582A1 (en) * | 2021-03-31 | 2024-06-06 | Janssen Biothech, Inc. | Materials and methods for immune effector cells redirection |
CN113980125B (zh) * | 2021-10-15 | 2024-03-26 | 中国科学院武汉病毒研究所 | 一种抗sftsv的中和性单克隆抗体及其应用 |
KR20230076376A (ko) | 2021-11-24 | 2023-05-31 | 대한민국(질병관리청 국립보건연구원장) | 중증열성혈소판감소증후군 바이러스 Gc 항원에 특이적으로 결합하는 항체 및 이의 용도 |
CN117229413A (zh) * | 2023-09-04 | 2023-12-15 | 中国人民解放军军事科学院军事医学研究院 | 一种针对SFTSV-Gn和CD3的双特异性抗体及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015053455A1 (ko) * | 2013-10-11 | 2015-04-16 | 서울대학교산학협력단 | 중증열성혈소판감소증후군 바이러스 및 이를 이용한 sfts 진단 방법 및 키트 |
CN105143261A (zh) * | 2013-01-31 | 2015-12-09 | 首尔大学校产学协力团 | C5抗体以及用于预防和治疗补体-相关的疾病的方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
US8372954B2 (en) * | 2000-12-22 | 2013-02-12 | National Research Council Of Canada | Phage display libraries of human VH fragments |
EP2298809A3 (en) * | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
CN1652821A (zh) * | 2002-01-28 | 2005-08-10 | 米德列斯公司 | 抗前列腺特异性膜抗原(psma)的人单克隆抗体 |
EP1851251A2 (en) * | 2005-02-18 | 2007-11-07 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
WO2010045388A2 (en) * | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis |
US20110286916A1 (en) * | 2008-11-20 | 2011-11-24 | Jose Miguel Aste-Amezaga | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
KR101093717B1 (ko) | 2008-11-26 | 2011-12-19 | 한국생명공학연구원 | Vegf―특이적인 인간항체 |
ES2751946T3 (es) * | 2009-03-20 | 2020-04-02 | Amgen Inc | Anticuerpo antagonista específico del heterodímero alfa-4-beta-7 |
WO2010141249A2 (en) * | 2009-06-02 | 2010-12-09 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-notch3 antibodies |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
WO2012048340A2 (en) | 2010-10-08 | 2012-04-12 | President And Fellows Of Harvard College | High-throughput immune sequencing |
GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
WO2012098089A1 (en) | 2011-01-19 | 2012-07-26 | Bayer Pharma Aktiengesellschaft | Binding proteins to inhibitors of coagulation factors |
US9574002B2 (en) * | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
SG11201401791WA (en) | 2011-10-24 | 2014-08-28 | Abbvie Inc | Immunobinders directed against sclerostin |
US9717803B2 (en) * | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
CN102942629B (zh) * | 2012-11-21 | 2014-03-19 | 江苏省疾病预防控制中心 | 一种抗sftsv的人源抗体 |
KR20210019491A (ko) * | 2016-03-23 | 2021-02-22 | 서울대학교산학협력단 | 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도 |
-
2017
- 2017-03-23 KR KR1020217000284A patent/KR20210019491A/ko not_active Application Discontinuation
- 2017-03-23 JP JP2018549916A patent/JP7328479B2/ja active Active
- 2017-03-23 AU AU2017237543A patent/AU2017237543B2/en not_active Ceased
- 2017-03-23 CN CN201780020024.5A patent/CN109071637B/zh active Active
- 2017-03-23 EP EP17770648.8A patent/EP3434690A4/en not_active Withdrawn
- 2017-03-23 WO PCT/KR2017/003156 patent/WO2017164678A2/ko active Application Filing
- 2017-03-23 US US16/086,761 patent/US10947299B2/en active Active
- 2017-03-23 MY MYPI2018703399A patent/MY196095A/en unknown
- 2017-03-23 KR KR1020197031770A patent/KR102201391B1/ko active IP Right Grant
- 2017-03-23 KR KR1020187030681A patent/KR102039189B1/ko active IP Right Grant
-
2020
- 2020-05-04 AU AU2020202948A patent/AU2020202948A1/en not_active Abandoned
-
2021
- 2021-02-09 US US17/171,044 patent/US20210171611A1/en not_active Abandoned
- 2021-06-30 JP JP2021109690A patent/JP7235256B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105143261A (zh) * | 2013-01-31 | 2015-12-09 | 首尔大学校产学协力团 | C5抗体以及用于预防和治疗补体-相关的疾病的方法 |
WO2015053455A1 (ko) * | 2013-10-11 | 2015-04-16 | 서울대학교산학협력단 | 중증열성혈소판감소증후군 바이러스 및 이를 이용한 sfts 진단 방법 및 키트 |
Non-Patent Citations (4)
Title |
---|
Human antibody neutralizes severe Fever with thrombocytopenia syndrome virus, an emerging hemorrhagic Fever virus;Guo Xiling 等;《Clinical and vaccine immunology》;20130717;第20卷(第9期);摘要,第1431页右栏第14-17行 * |
Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines;Hofmann Heike 等;《Journal of virology》;20130206;第87卷(第8期);4384-4394 * |
Systematic review of severe fever with thrombocytopenia syndrome:virology, epidemiology, and clinical characteristics;Shelan Liu 等;《Reviews in Medical Virology》;20131206;第24卷;90-102 * |
抗发热伴血小板减少综合征病毒结构蛋白单克隆抗体的制备和功能分析;李阿茜 等;《病毒学报》;20150101;第31卷(第1期);摘要,第22页左栏最后一段 * |
Also Published As
Publication number | Publication date |
---|---|
JP7328479B2 (ja) | 2023-08-17 |
US20210171611A1 (en) | 2021-06-10 |
AU2020202948A1 (en) | 2020-05-21 |
JP2021184710A (ja) | 2021-12-09 |
WO2017164678A2 (ko) | 2017-09-28 |
MY196095A (en) | 2023-03-14 |
EP3434690A4 (en) | 2020-04-01 |
JP2019516348A (ja) | 2019-06-20 |
AU2017237543A1 (en) | 2018-10-04 |
JP7235256B2 (ja) | 2023-03-08 |
KR102039189B1 (ko) | 2019-11-01 |
WO2017164678A3 (ko) | 2018-09-07 |
US20190112360A1 (en) | 2019-04-18 |
KR102201391B1 (ko) | 2021-01-11 |
KR20210019491A (ko) | 2021-02-22 |
EP3434690A2 (en) | 2019-01-30 |
CN109071637A (zh) | 2018-12-21 |
AU2017237543B2 (en) | 2020-02-06 |
US10947299B2 (en) | 2021-03-16 |
KR20180122456A (ko) | 2018-11-12 |
KR20190123816A (ko) | 2019-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109071637B (zh) | 结合严重发热伴血小板减少综合征病毒的包膜糖蛋白的抗体及其用途 | |
CN111620945B (zh) | 一种抗新型冠状病毒的单克隆抗体或其衍生体 | |
CN111560070B (zh) | 针对新型冠状病毒np蛋白的抗体及其检测应用 | |
KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
EP3712170A1 (en) | Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof | |
CN110642944B (zh) | 一种中和人感染h7n9甲型流感病毒的抗体及其用途 | |
WO2006089141A2 (en) | Antibodies against cxcr4 and methods of use thereof | |
KR20150001728A (ko) | Cdim 결합 단백질 및 이의 용도 | |
US9550825B2 (en) | Humanized anti-HMGB1 antibody or antigen-binding fragment thereof | |
CN109957011B (zh) | 抗h7n9全人源单克隆抗体6e9及其制法与应用 | |
CN109957012B (zh) | 抗h7n9全人源单克隆抗体8e17及其制法与应用 | |
CN107286237B (zh) | 一种抗丙型肝炎病毒抗体的获取以及应用 | |
CN114805570B (zh) | 一种抗人ace2单克隆抗体及其应用 | |
CN109957013B (zh) | 抗h7n9全人源单克隆抗体7o2及其制法与应用 | |
CN109957010B (zh) | 抗h7n9全人源单克隆抗体5g22及其制法与应用 | |
JP2023547167A (ja) | コロナウイルススパイクタンパク質に特異的な抗体及びその用途 | |
CN115073593A (zh) | 新型冠状病毒抗体及其用途 | |
CN114790239A (zh) | 一种抗冠状病毒n蛋白的抗体及其应用 | |
WO2021237051A1 (en) | SARS-CoV-2 ANTIBODY AND RELATED METHODS | |
CN116478288A (zh) | 红细胞弱结合型人源化cd47抗体及其应用 | |
KR20230076376A (ko) | 중증열성혈소판감소증후군 바이러스 Gc 항원에 특이적으로 결합하는 항체 및 이의 용도 | |
CN115028714A (zh) | 一种检测冠状病毒的抗体及其应用 | |
KR20230038028A (ko) | 코로나바이러스 스파이크 단백질에 특이적인 항체 및 이의 용도 | |
CN115850458A (zh) | 一种抗冠状病毒rbd蛋白的抗体、制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1260815 Country of ref document: HK |
|
CB03 | Change of inventor or designer information |
Inventor after: Zheng Junhao Inventor after: Jin Qixian Inventor after: Jin Xiaoli Inventor after: Wu Mingdun Inventor after: Pu Wanfan Inventor after: Jin Chengze Inventor after: Jin Zhenxi Inventor after: Min Zhiying Inventor after: Gao Meixian Inventor before: Zheng Junhao Inventor before: Jin Qixian Inventor before: Jin Xiaoli Inventor before: Wu Mingdun Inventor before: Pu Wanfan Inventor before: Jin Chengze Inventor before: Jin Zhenxi |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |